<DOC>
	<DOC>NCT02193334</DOC>
	<brief_summary>This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for acute spinal cord injury. The study is conducted at two clinical sites in Japan.</brief_summary>
	<brief_title>Phase I/II Study of KP-100IT in Acute Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age equal to or greater than 18 years and equal to or less than 75 years Cervical spinal cord injury, and Grade A, B1 or B2 in the modified Frankel Scale at 72 hours since the injury Subjects able to provide written informed concent, which may require a relative to sign if arm/hand function of the subject is compromised Spinal cord injury at C1C2 0r C2C3 level Patients not to able to start rehabilitation within a week by setup of respirator or other reason First dose of the study drug will not be given within 78 hours since the injury History of spinal cord injury or abnormality in spinal cavity. Or current considerable meningeal damage Outcome assessment will not be conducted adequately through damage on injuries other than the injury Highdose steroid therapy within 30 days before the entry Patients who have diseases such as serious liver disorder, renal disorder, hear disease, blood dyscrasia, metabolism disorder and infections History of malignant tumor Patients who participated in other clinical study within 30 days before the entry Patients who have allergies to drug scheduled to be used in the study Administration of the study drug to the area of spinal cord injury is not appropriate for example by intrathecal infections or intrathecal tumor Patients not able to understand "informed consent" properly Patients who are nursing or may be pregnant Investigator considers that the patient is not appropriate for participating in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hepatocyte Growth Factor</keyword>
	<keyword>HGF</keyword>
	<keyword>KP-100IT</keyword>
	<keyword>Intrathecal injection</keyword>
</DOC>